Drug extends animal life by activating ‘energy saver’ mode
Scientists have successfully used a drug to prolong the lifespan of several species of animals, in some cases by more than 25%.
The study, published in Aging Cell, found strong evidence that triggering a protein, governing energy levels, may help organisms live significantly longer.
Researchers from the MRC Laboratory of Medical Sciences (MRC LMS), Imperial College London, University of Cologne, and their collaborators used a drug to activate an important metabolic sensor in cells and achieved anti-ageing effects across a range of species including yeast, worms and flies.
AMPK is a special metabolic enzyme inside cells that monitors energy levels in real time. When energy depletes, for instance during exercise, fasting or stress, then AMPK turns off intensive cellular processes like building new proteins or storing fat. Instead, AMPK turns on energy-generating processes, such as burning existing fat and sugar for fuel.
The role of AMPK
Since AMPK plays such a central role in controlling metabolism, disruption of AMPK can lead to metabolic diseases, such as type 2 diabetes and obesity, while increased AMPK activity can help provide health benefits. Several medicines and treatments including the anti-diabetic drug Metformin and weight-loss drugs like Semaglutide are known to activate AMPK, but many of these work indirectly, making it much more challenging to confirm and interpret biological results with certainty in the laboratory and in the clinic.
To overcome this hurdle, the team used a specific drug, called ‘991’, to target AMPK directly, turning to a range of model organisms: fission yeast (S. pombe), nematode worms (C. elegans) and fruit flies (Drosophila). These model systems are extremely valuable in the ageing field, due to their comparatively short lifespans.
Dr Helena Cochemé, Head of the Redox Metabolism Group, MRC LMS, says that extending lifespan in yeast, worms and flies is promising because these shorter-lived models allow faster research. The study is the first to show that directly targeting AMPK with a drug can extend lifespan, increasing confidence that the approach could eventually translate to mammals and humans.
Professor David Carling, Head of the Cellular Stress Group, MRC LMS, says that direct AMPK activation produces a cleaner effect with fewer potential side-effects. The next step is testing whether it can improve health and extend lifespan in mice; existing clinical trials of AMPK activators for metabolic diseases provide a basis for future applications.
Professor Filipe Cabreiro, Head of the Host-Microbe Co-Metabolism Group, MRC LMS and University of Cologne, added that human anti-ageing trials remain a long way off because ageing is not classified as a disease. However, extending healthy lifespan could have major societal and healthcare benefits by reducing age-related diseases, with AMPK targeting a potentially important route.
The research also involved contributions from scientists at Queen Mary University of London, the Francis Crick Institute, and the University of Lyon.
This study was primarily publicly funded by the Medical Research Council, part of UKRI.
